Condition: Chronic Migraine · Sponsor: University of Manitoba
Chronic headaches are a major cause of disability among adolescents. Cannabis products have supported the management of headaches in adults and may play a role in pediatric chronic pain. We propose a multisite, open-label, tolerability study conducted across three centers in Canada of Cannabidiol-enriched Cannabis Herbal Extract in adolescents (ages 14 to 17 years old) with chronic headaches. The study includes a one month baseline assessment, four months of escalating treatment doses and a weaning period. Our primary outcome is tolerability defined as the number and severity of reported adverse events.
This description comes directly from the study's public registry record.
Lauren E Kelly, PhD · 2042723149 · lauren.kelly@umanitoba.ca
Lauren Kelly · 2042723149 · lauren.kelly@umanitoba.ca
Always discuss trial participation with your own doctor first.
| University of British Columbia | Vancouver, British Columbia, Canada | Not Yet Recruiting |
| Dalhousie University- | Halifax, Nova Scotia, Canada | Not Yet Recruiting |
| North Toronto Neurology | Toronto, Ontario, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05337033